Recent

% | $
Quotes you view appear here for quick access.

ALLIQUA, INC. Message Board

  • bookokane bookokane Aug 11, 2013 2:06 PM Flag

    Super Honey

    Read this boys and girls-/www.dailymail.co.uk/health/article-2389121/Doctors-discover-super-honey-amazing-power-treat-soldiers-wounds-kill-superbug-infections.html - and see how this could be some major competition, to say the least!

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Traditional Adhesive Dressings
      Traditional Gauze Dressings
      Non-Adherent Dressings
      Film Dressings
      Foam Dressings
      Hydrogel Dressings
      Hydrocolloid Dressings
      Alginate Dressings
      Antimicrobial Dressings
      Negative Pressure Wound Therapy Devices
      Bioengineered Skin and Skin Substitutes
      Wound Care Growth Factors
      The world market in 2012 stood at approximately $11.7 billion. By 2021, the total wound management market represented by the segments listed above is projected to be worth over $18.5 billion million, with a 2013-2021
      CAGR over 7%.
      The diabetic foot is the most common cause of non-traumatic lower extremity amputations in the US and Europe: there is an average of 82,000 amputations per year in the U.S., costing an estimated $1.6 billion annually. The estimated cost of foot ulcer care in the U.S. ranges from $4,595 per ulcer episode to more than $28,000 and the total annual cost of foot ulcer care in the US has been estimated to be as high #$%$ billion.

      In 2009, four companies (Johnson and Johnson, Kinetic Concepts Inc., Hill-Rom and Smith & Nephew) were responsible for about 60 percent of total market revenue. However, mergers, acquisitions and sales of intellectual property have rapidly changed the market share picture. By the end of 2012, more than half of the global wound care market was held by Johnson and Johnson, 3M, Smith & Nephew, and Systagenix. In addition, competition on price has driven down prices in the well established (i.e., traditional wound care) markets, while novel technologies are taking hold with introductory revenues and generating high, early stage growth rates.

      So as you all can see there is more than enough room for ALQA to take a bite of the big pie that is the wound care market, here in the USA globally, or even a possible buy out down the road.

      • 1 Reply to amadeus942000
      • I agree, I have been involved in Biotech and Bio-Medical Device R&D, and Manufacturing for over 25 years. I am only working cause I got bored. Small Biotech's made me a lot of money from my stock options and investments in micro's of this industry. I love going to work as a contract employee for them and take pay in stock options.
        I have been watching for a while and investing at the right times, especially lower values.

        I see this company's patents, and mergers as a plus, and forward looking as a LONG. It is not just wound care and hepatic treatments.
        The technology in Alliqua's is the future of bio and pharma drugs. More and more treatments are going topical patches.
        Many negative posters on hear have blinders on, and only come out to give negatives to try and get their shorting met.

        I have a fellow vet who has gotten Alliqua's patch in testing at the VAMC. It is a plus for him, he will not lose his foot from nephritic lesions that would not heal. Other treatments were not working. All I can say is sit back be patient and watch.

        At this price, instead of wasting thousands playing the lottery and scratch offs, invest in the small guys, better odds.

        Sentiment: Buy